Status:
COMPLETED
Study In Patients With Kidney Cancer Treated With Sutent
Lead Sponsor:
Pfizer
Conditions:
Advanced or Metastatic Renal Cell Carcinoma
Renal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Objective of this study is to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib.
Detailed Description
Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy
Eligibility Criteria
Inclusion
- Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy
Exclusion
- Hypersensitivity to sunitinib malate or to any of the excipients
- Any other contraindication to the use of sunitinib malate (based on decision of the treating physician).
Key Trial Info
Start Date :
May 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2011
Estimated Enrollment :
121 Patients enrolled
Trial Details
Trial ID
NCT00873210
Start Date
May 1 2009
End Date
November 1 2011
Last Update
November 9 2012
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Banská Bystrica, Slovakia, 975 17
2
Pfizer Investigational Site
Bojnice, Slovakia, 972 01
3
Pfizer Investigational Site
Bratislava, Slovakia, 812 50
4
Pfizer Investigational Site
Bratislava, Slovakia, 833 10